Results 11 to 20 of about 2,146 (159)

Ravulizumab exposure in early pregnancy

Annals of Hematology
Before complement inhibitors were available, pregnancy in women with paroxysmal nocturnal hemoglobinuria (PNH) was associated with considerable mortality, mainly due to thromboembolism.
Wolfgang Füreder, Sonja Granser, Andreas Repa, Alex Farr   +3 more
doaj   +3 more sources

Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence

Neuropsychiatric Disease and Treatment, 2023
Tuan Vu,1 Heinz Wiendl,2 Masahisa Katsuno,3 Stephen W Reddel,4 James F Howard Jr5 1Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, FL, USA; 2Department of Neurology with Institute of Translational Neurology ...
Vu T, Wiendl H, Katsuno M, Reddel SW, Howard JF Jr   +4 more
doaj   +3 more sources

Current Opinions on the Clinical Utility of Ravulizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

Therapeutics and Clinical Risk Management, 2021
Carmelo Gurnari,1,2 Ishani Nautiyal,1 Simona Pagliuca1,3 1Department of Translational Hematology and Oncology Research, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH, USA; 2Department of Biomedicine and Prevention, PhD in Immunology ...
Carmelo Gurnari, Simona Pagliuca
exaly   +2 more sources

Atypical Hemolytic Uremic Syndrome Associated With Malignant Hypertension Presenting With Pulmonary-Renal Syndrome-like Symptoms [PDF]

Kidney Medicine
Both atypical hemolytic uremic syndrome (aHUS) and malignant hypertension (MHT) are causes of thrombotic microangiopathy (TMA), and their coexistence has been reported. We describe a 22-year-old man who exhibited severe hypertension, pulmonary hemorrhage,
Hiroyuki Okawa, Yukihiro Wada, Noritoshi Kato, Mayuko Hanyuda, Ryota Uchitubo, Tetsuya Abe, Kazuhiro Takeuchi, Yasushi Nagaba, Shoichi Maruyama, Yasuo Takeuchi   +9 more
doaj   +2 more sources

Practical Guidance on Initiating and Switching Targeted Immunotherapies in Generalised Myasthenia Gravis: A German-Austrian Expert Opinion Paper. [PDF]

Eur J Neurol
ABSTRACT Background The therapeutic landscape of generalised myasthenia gravis (gMG) has evolved substantially with the approval of targeted immunotherapies, including complement C5 inhibitors (C5‐I) and neonatal Fc receptor inhibitors (FcRn‐I). While pivotal trials have demonstrated marked efficacy in defined subgroups, real‐world experience reveals ...
Meisel A, Marina AD, Doksani P, Hagenacker T, Kleinschnitz C, Krämer HH, Lünemann JD, Meuth SG, Ruck T, Schara-Schmidt U, Schneider-Gold C, Schoser B, Schroeter M, Schubert C, Sieb JP, Zimprich F, Zschüntzsch J, Hoffmann S.   +17 more
europepmc   +2 more sources

Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis

Neurology and Therapy, 2023
This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare ...
Tuan Vu, Andreas Meisel, Renato Mantegazza, Djillali Annane, Masahisa Katsuno, Rasha Aguzzi, Ahmed Enayetallah, Kathleen N. Beasley, Nishi Rampal, James F. Howard   +9 more
doaj   +1 more source

Atypical Hemolytic Uremic Syndrome Treated With Ravulizumab or Eculizumab: A Claims-Based Evaluation of Health Care Resource Utilization and Clinical Outcomes in the United StatesPlain language summary

Kidney Medicine, 2023
Rationale and Objective: Ravulizumab and eculizumab have shown efficacy for the treatment of atypical hemolytic uremic syndrome (aHUS), but real-world evidence for ravulizumab is limited owing to its more recent approval.
Yan Wang, Imad Al-Dakkak, Katherine Garlo, Moh-Lim Ong, Ioannis Tomazos, Arash Mahajerin   +5 more
doaj   +1 more source

One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study

Therapeutic Advances in Hematology, 2020
Background: Ravulizumab, the only long-acting complement C5 inhibitor for adults with paroxysmal nocturnal hemoglobinuria (PNH), demonstrated non-inferiority to eculizumab after 26 weeks of treatment in complement inhibitor-naïve patients during a phase ...
Hubert Schrezenmeier, Austin Kulasekararaj, Lindsay Mitchell, Flore Sicre de Fontbrune, Timothy Devos, Shinichiro Okamoto, Richard Wells, Scott T. Rottinghaus, Peng Liu, Stephan Ortiz, Jong Wook Lee, Gérard Socié   +11 more
doaj   +1 more source

Ravulizumab in pregnancy: the case for cautious optimism. [PDF]

Blood Adv
Shammo JM.
europepmc   +2 more sources

Ravulizumab (Ultomiris)

Canadian Journal of Health Technologies, 2022
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire   +2 more sources